Source: Annual Congress 2006 - Recent advances in treatment of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Kinoshita, T. Kawayama, T. Hoshino, S. Minami, M. Ichiki, M. Nishiyama, Y. Sueyasu, R. Gohara, M. Kinoshita, T. Mitsui, H. Koga, H. Aizawa (Kurume, Japan). Clinical efficacy of transdermal tulobuterol patch in patients with chronic obstructive pulmonary disease: a comparison with slow-release theophyline. Eur Respir J 2006; 28: Suppl. 50, 1279

Member's Comments

No comment yet.

Related content which might interest you: Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Efficacy and cardiovascular safety of long-term bronchodilator therapy with theophylline in patients with chronic obstructive bronchitis (COB) Source: Eur Respir J 2003; 22: Suppl. 45, 52s Year: 2003 Effects of combined therapy with nebulized b2-agonist and anticholinergic in severe exacerbation of chronic obstructive pulmonary disease. Randomized controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007 Efficacy of lasolvan in the treatment of patients with chronic obstructive pulmonary disease Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 1075 Year: 2004 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Source: Eur Respir J 2003; 21: 912 Year: 2003 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003 A comparison of bronchodilating response of salbutamol, ipratropium bromide and the combination of ipratropium-salbutamol in patients with stable chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001 Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001 The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 Evaluation of the efficacy and safety of two formulations of Ipratropium bromide HFA pMDI in patients with mild to moderate chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 A comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a double-blind, efficacy and safety study in Chinese adults with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 213s Year: 2006 Efficacy of budesonide/formoterol in Chinese patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001 COPD and concomitant arterial hypertension: The efficacy and safety of slow-release formulation of indapamide Source: International Congress 2014 – Clinical presentations Year: 2014 Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2007; 30: Suppl. 51, 357s Year: 2007 Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002 Triple therapy with Fluticasone furoate/Umeclidinium/Vilanterol compared with dual bronchodilation or triple therapy with inhaled corticosteroids/dual bronchodilation in patients with chronic obstructive pulmonary disease Source: Virtual Congress 2020 – Investigations of COPD Year: 2020